The fourth edition of the World Health Organization (WHO) classification of urogenital tumours
(WHO “blue book”), published in 2016, contains significant revisions. These revisions …

This paper presents the conclusions of a workshop entitled ‘Impact of Molecular Genetics
on the Classification of Renal Cell Tumours’, which was held in Heidelberg in October 1996. …

It has been 12 yr since the publication of the last World Health Organization (WHO) classification
of tumours of the prostate and bladder. During this time, significant new knowledge has …

Annotation of prostate cancer genomes provides a foundation for discoveries that can
impact disease understanding and treatment. Concordant assessment of DNA copy number, …

Toward development of a precision medicine framework for metastatic, castration-resistant
prostate cancer (mCRPC), we established a multi-institutional clinical sequencing …

We report a comprehensive analysis of 412 muscle-invasive bladder cancers characterized
by multiple TCGA analytical platforms. Fifty-eight genes were significantly mutated, and the …

The development of decision support systems for pathology and their deployment in clinical
practice have been hindered by the need for large manually annotated datasets. To …

Background Despite revisions in 2005 and 2014, the Gleason prostate cancer (PCa)
grading system still has major deficiencies. Combining of Gleason scores into a three-tiered …

Purpose: Three-dimensional conformal radiation therapy (3D-CRT) is a technique designed
to deliver prescribed radiation doses to localized tumors with high precision, while …

Prostate-specific membrane antigen (PSMA) is a type II integral membrane glycoprotein that
was initially characterized by the monoclonal antibody (mAb) 7E11. PSMA is highly …